Stocks Health care KAPA
NYSE · Health careKairos Pharma, LTD. (KAPA)
It posted a net loss of $5.8M. At June 30, 2026 it held $2.6M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
Key facts about Kairos Pharma, LTD.
- Net worth
- Kairos Pharma, LTD. has a market value (market cap) of $11.2M at the latest share price, and shareholders' equity of $4.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $3.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 12, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Kairos Pharma, LTD.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Kairos Pharma, LTD. does
Kairos Pharma, LTD. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker KAPA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$5.4M | -$0.30 | n/a |
| 2024 | n/a | -$2.6M | -$0.23 | n/a |
| 2024 | n/a | -$1.8M | -$0.17 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Kairos Pharma, LTD. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026Other event 8-K
- September 14, 2026
- August 21, 2026
- August 12, 2026
- July 22, 2026
- July 15, 2026Other event 8-K
- June 30, 2026
- June 4, 2026Other event 8-K
- May 26, 2026Additional proxy material DEFA14A
- May 22, 2026
Insider trades
What the people running Kairos Pharma, LTD. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns KAPA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
7 insiders reported holding 2,286,070 shares in total, about $1.1M at the last price.
| Holder | Shares |
|---|---|
| Bhowmick NeilChief Scientific Officer | 1,311,739 |
| Murali RamachandranVP of Research and Development | 299,529 |
| Samuelson DougChief Financial Officer | 293,039 |
| Yu John SCEO and Chairman, Director, 10% owner | 230,105 |
| Bae Hyun W.Director | 73,370 |
| Singhvi RahulDirector | 49,204 |
| Keyoung Hansoo MichaelDirector | 29,084 |
Questions about KAPA
What does Kairos Pharma, LTD. do?
Kairos Pharma, LTD. is a company in the Health care sector, listed on NYSE as KAPA. Its shares trade on NYSE under the ticker KAPA.
What is Kairos Pharma, LTD.'s net worth?
Kairos Pharma, LTD. has a market value (market cap) of $11.2M at the latest share price, and shareholders' equity of $4.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Kairos Pharma, LTD. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $5.8M.
When did Kairos Pharma, LTD. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the other event from October 6, 2026.
When is Kairos Pharma, LTD.'s next earnings report?
Kairos Pharma, LTD.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare KAPA with
Follow KAPA
Get an email when Kairos Pharma, LTD. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Kairos Pharma, LTD. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.